OLIGONUCLEOTIDES-TRANSFERRING PREPARATIONS

• US 20110028535A1
• Filed: 10/13/2010
• Published: 02/03/2011
• Est. Priority Date: 06/20/2000
• Status: Abandoned Application

• Current Assignee: Koken Limited, National Cancer Center, Dainippon Sumitomo Pharma Company Limited (Sumitomo Chemical Company Limited)
• Original Assignee: Koken Limited, National Cancer Center, Dainippon Sumitomo Pharma Company Limited (Sumitomo Chemical Company Limited)
• Inventors: Ochiya, Takahiro, Furuse, Masayasu, Itoh, Hiroshi, Sano, Akihiko, Nagahara, Shunji, Terada, Masaaki, KUBOTA, Shunichiro
• Application Number:
  US12/904,054
• Publication Number:
  US 20110028535A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: A61K 31/7105 Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 31/711 Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
• CPC Class Codes: A61K 47/42 Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein oligopeptides having up to five amino acids A61K47/183; polyamino acids A61K47/34
• CPC Class Codes: A61K 48/00 Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
• CPC Class Codes: A61K 48/0008 characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
• CPC Class Codes: A61K 9/0019 Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner non-active ingredients are additionally classified in A61K47/00
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61K 9/127 Liposomes
• CPC Class Codes: A61K 9/19 lyophilised , i.e. freeze-dried, solutions or dispersions lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00
• CPC Class Codes: A61K 9/2063 Proteins, e.g. gelatin
• CPC Class Codes: A61K 9/7007 Drug-containing films, membranes or sheets A61K9/0041, A61K9/0043, A61K9/006, A61K9/0063 take precedence
• CPC Class Codes: A61P 35/00 Antineoplastic agents

Abstract

Preparations for transferring efficiently oligonucleotides necessary in antisense therapy or the like into animal cells so as to be useful in treatment for various diseases, which comprises a collagen as an essential component are provided.

Claims

1. An article from which an oligonucleotide is released comprising an oligonucleotide of 5 to 30 nucleotides in length and a water soluble atelocollagen that has a degree of cross-linking of 3 or less.

2. The article of claim 1, in which the atelocollagen has a molecular weight of 300,000 to 900,000 daltons.

3. The article of claim 1, in which the atelocollagen is a water soluble type I atelocollagen.

4. The article of claim 1, in which the oligonucleotide has at least one phosphorothioate bond.

5. The article of claim 1, in which the oligonucleotide inhibits expression of a target mRNA.

6. The article of claim 1, in which the oligonucleotide has a base sequence complementary to a sequence of a target mRNA or of a target mRNA precursor.

7. The article of claim 1, in which the oligonucleotide is a DNA or a DNA derivative.

8. The article of claim 1, in which the oligonucleotide is a RNA or a RNA derivative.

9. A water soluble article from which an oligonucleotide is released comprising an oligonucleotide of 5 to 30 nucleotides in length and a water soluble type I atelocollagen.

10. The article of claim 9, in which the atelocollagen has a molecular weight of 300,000 to 900,000 daltons.

11. The article of claim 9, in which the oligonucleotide has at least one phosphorothioate bond.

12. The article of claim 9, in which the oligonucleotide inhibits translation of a target mRNA.

13. The article of claim 9, in which the oligonucleotide has a base sequence complementary to a sequence of a target mRNA or of a target mRNA precursor.

14. The article of claim 9, in which the oligonucleotide is a DNA or a DNA derivative.

15. The article of claim 9, in which the oligonucleotide is a RNA or a RNA derivative.

16. A solution comprising an oligonucleotide of 5 to 30 nucleotides in length and a water soluble atelocollagen that has a degree of cross-linking of 3 or less.

17. The solution of claim 16, in which the atelocollagen has a molecular weight of 300,000 to 900,000 daltons.

18. The solution of claim 16, in which the atelocollagen is a type I atelocollagen.

19. The solution of claim 16, in which the oligonucleotide has at least one phosphorothioate bond.

20. The solution of claim 16, in which the oligonucleotide inhibits expression of a target mRNA.

21. The solution of claim 16, in which the oligonucleotide has a base sequence complementary to a sequence of a target mRNA or of a target mRNA precursor.

22. The solution of claim 16, in which the oligonucleotide is a DNA or a DNA derivative.

23. The solution of claim 16, in which the oligonucleotide is a RNA or a RNA derivative.

24. A water soluble article from which an oligonucleotide is released consisting essentially of an oligonucleotide of 5 to 30 nucleotides in length and a water soluble atelocollagen that has a degree of cross-linking of 3 or less.

25. The article of claim 24, in which the atelocollagen has a molecular weight of 300,000 to 900,000 daltons.

26. The article of claim 24, in which the atelocollagen is a water soluble type I atelocollagen.

27. The article of claim 24, in which the oligonucleotide has at least one phosphorothioate bond.

28. The article of claim 24, in which the oligonucleotide inhibits expression of a target mRNA.

29. The article of claim 24, in which the oligonucleotide has a base sequence complementary to a sequence of a target mRNA or of a target mRNA precursor.

30. The article of claim 24, in which the oligonucleotide is a DNA or a DNA derivative.

31. The article of claim 24, in which the oligonucleotide is a RNA or a RNA derivative.

32. A water soluble article consisting essentially of an oligonucleotide of 5 to 30 nucleotides in length and a water soluble type I atelocollagen.

33. The article of claim 32, in which the atelocollagen has a molecular weight of 300,000 to 900,000 daltons.

34. The article of claim 32, in which the oligonucleotide has at least one phosphorothioate bond.

35. The article of claim 32, in which the oligonucleotide inhibits translation of a target mRNA.

36. The article of claim 32, in which the oligonucleotide has a base sequence complementary to a sequence of a target mRNA or of a target mRNA precursor.

37. The article of claim 32, in which the oligonucleotide is a DNA or a DNA derivative.

38. The article of claim 32, in which the oligonucleotide is a RNA or a RNA derivative.